Navigation Links
Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting
Date:6/8/2009

t-Batar, A., and Minnasch, P.

Method

Responder analysis of at least 1-point improvement from baseline to week 4 on the Disability Assessment Scale [DAS] for the primary therapeutic target after injection of a 20 U/mL dilution or 50 U/mL dilution was evaluated. After injection, observation over a 12-week period was followed by 8 weeks safety follow-up. Botulinum neurotoxin doses were derived from the recommendations from the organization WE MOVE. The individual injection pattern was adapted to patient's needs. A two-sided 95% Newcombe-Wilson confidence interval [CI] for the difference between groups was calculated.

Results

192 patients with upper limb spasticity caused by either stroke (88%), brain injury (5.7%), multiple sclerosis (0.5%) or cerebral palsy (1.6%) were randomized to the 50 U/mL dilution group (95 patients) or to the 20 U/mL dilution group (97 patients). Limb position (60.4%), Dressing (24.0%), Hygiene (9.4%) and Pain (6.3%) were chosen as primary therapeutic target on the DAS. The maximum injected total dose was 495 units NT 201. Four weeks after injection 57.1% of patients had an at least 1-point DAS reduction from the baseline score for their primary therapeutic target. No dilution group was inferior to each other regarding efficacy. 79.9% of patients and 89.0% of investigators reported an improvement in global assessment of efficacy at week 4. There were no relevant differences regarding safety between groups.

About Merz

Merz (KGAa) is known worldwide for its development of original compounds and formulations for medical professionals and consumers in 90 countries. Globally, Merz is a leader in research and development of pharmaceuticals for the treatment of neurological and psychological disorders as well as for aesthetic dermatology, including products for the treatment of wrinkles and aging skin, hair loss and acne. Research is concentrated in fi
'/>"/>

SOURCE Merz Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk
2. Access Pharmaceuticals Announces Publication of Thiarabine Combination Data
3. Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials
4. Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Associations 69th Scientific Sessions
5. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
6. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
7. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
8. Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
9. Kinex Pharmaceuticals To Present at ASCO 2009 Annual Meeting
10. TRACON Pharmaceuticals Small Molecule TRC102 and Antibody TRC105 to be Presented at ASCO 2009
11. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Australia , Sept. 18, 2014 Veterinary ... of Dr. Ashraf Hanna , M.D., Ph.D., and ... Board of Directors. Dr. Hanna is the Vice President ... Chief Financial Officer for the Genentech Foundation, while Dr. ... Head of Business Development and Licensing for Roche Pharma. ...
(Date:9/18/2014)... 18, 2014  Spring Bank Pharmaceuticals, Inc., a ... treatment of RNA viruses, today announced a research ... for animal testing of the Company,s lead compound, ... "Special Pathogens," against which currently there are no ... Spring Bank,s proprietary Small Molecule Nucleic Acid ...
(Date:9/18/2014)...   Auxilium Pharmaceuticals, Inc. (NASDAQ: ... announced the first presentation of positive safety and ... Investigation of Collagenase Optimizing the Resolution of Dupuytrens) ... histolyticum (CCH) for the treatment of two Dupuytren,s ... the study examined expanded flexibility with timing of ...
Breaking Medicine Technology:Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 2Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 3Spring Bank Pharmaceuticals Announces NIH Collaboration for Testing of SB 9200 Against Multiple Viral Pathogens 2Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 2Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 3Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 4Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 5Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 6Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 7
(Date:9/18/2014)... 18, 2014 TayganPoint Consulting Group, ... that President and co-founder John Cassimatis was named ... Winners for 2014, recognizing the region’s top healthcare ... emerging executive of the year. , The Innovation ... sciences that continue to shape the medical industry ...
(Date:9/18/2014)... GA (PRWEB) September 18, 2014 Ben ... the Alex Ormond, Jr. Leadership Award by the Savannah ... improving healthcare and wellness throughout the nation and especially ... receive this award,” said Ben. “The Savannah Science Seminar ... 65 years and multiple generations have gone through the ...
(Date:9/18/2014)... have developed a new method to study Ebola virus ... Wildlife Conservation Society (WCS)-led research, published today in the ... use of fecal samples from wild great apes to ... virus. This represents a new tool for performing large, ... Ebola virus is studied and improve our understanding of ...
(Date:9/18/2014)... (September 18, 2014) The National Institutes of Health ... a four-year, $1.3 million grant to the Los Angeles ... research and development of a vaccine to protect patients ... Staphylococcus aureus (MRSA). , The National ... NIH awarded the grant to LA BioMed infectious disease ...
(Date:9/18/2014)... trying to develop tools that would allow them to ... moment a neuron fires to the resulting behavior in ... are working to develop a range of new tools ... one such tool that provides a new way of ... worka collaboration between Viviana Gradinaru (BS ,05), assistant professor ...
Breaking Medicine News(10 mins):Health News:TayganPoint Executive Receives Prestigious Award from Philadelphia Business Journal 2Health News:Quirk Awarded the Alex Ormond, Jr. Leadership Award by the Savannah Science Seminar 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 3Health News:LA BioMed receives NIH grant to study vaccine for hospital-acquired infections 2Health News:Sensing neuronal activity with light 2Health News:Sensing neuronal activity with light 3Health News:Sensing neuronal activity with light 4Health News:Sensing neuronal activity with light 5
... Brophy Marcus HealthDay Reporter , WEDNESDAY, Oct. 5 ... after a kidney transplant allows some patients to cast away ... new organ, according to a small new study from the ... in the United States and while they can greatly improve ...
... Steven Reinberg HealthDay Reporter , WEDNESDAY, Oct. 5 ... tip-top health may have a greater risk of developing dementia ... Oct. 5 issue of the journal Neurology . ... simple tool for doctors to determine a person,s risk of ...
... WEDNESDAY, Oct. 5 (HealthDay News) -- The death toll from ... risen to 18, and a total of 100 people have ... Control and Prevention reported late Tuesday. The agency said ... 14, more cases might still emerge since Listeria monocytogenes ...
... from Mount Sinai School of Medicine have found high ... (AGEs) in infants. Excessive food AGEs, through both maternal ... children,s risk for diseases such as diabetes from a ... adults found that cutting back on processed, grilled, and ...
... (HealthDay News) -- Scientists who taught monkeys to use their ... virtual body) and to identify the texture of virtual objects ... for people who,ve suffered crippling spinal injuries. "Someday in ... technology not only to move their arms and hands and ...
... (October 5, 2011)Prostate cancer is the most common cancer ... the second leading cause of cancer-related deaths in this ... their prostate, followed by radiation therapy applied to their ... once situated. The most common technique of ...
Cached Medicine News:Health News:Stem Cell Therapy Might Help Kidney Transplant Patients 2Health News:Stem Cell Therapy Might Help Kidney Transplant Patients 3Health News:Stem Cell Therapy Might Help Kidney Transplant Patients 4Health News:Gauging General Health as 'Poor' May Point to Dementia Risk 2Health News:18 Deaths From Cantaloupe-Linked Listeria Outbreak: CDC 2Health News:18 Deaths From Cantaloupe-Linked Listeria Outbreak: CDC 3Health News:New study shows inflammatory food toxins found in high levels in infants 2Health News:New study shows inflammatory food toxins found in high levels in infants 3Health News:Monkeys Use Brain Power, Not Hands, to 'Move' Virtual Objects 2Health News:Fox Chase researchers improve accuracy of IMRT delivery in post-prostatectomy patients 2Health News:Fox Chase researchers improve accuracy of IMRT delivery in post-prostatectomy patients 3
Our Osteomark® ELISA kits provide a quantitative measurement of cross-linked N-telopeptides of type I collagen (NTx) as an indicator of bone resorption, with higher levels in serum or urine sampl...
Our Osteomark® ELISA kits provide a quantitative measurement of cross-linked N-telopeptides of type I collagen (NTx) as an indicator of bone resorption, with higher levels in serum or urine sampl...
... Cobalt Binding (ACB®) Test is a clinical ... (IMA®) by measuring the cobalt binding capacity ... First identified in the early 1990s, IMA ... contact with ischemic tissue in the heart. ...
Inquire...
Medicine Products: